Conkwest Appoints New Co-Chairman And Receives $50m Investment For Development of Immunotherapies
News
Conkwest, Inc., a company developing the proprietary immunotherapeutic Natural Killer (NK) cell-line platform, Neukoplast (NK-92), has announced that physician scientist Dr. Patrick Soon-Shiong, NantWorks founder, has agreed to acquire almost $48 ... Read more